Company Overview - CollPlant Biotechnologies is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics [2] - The company's products are based on rhCollagen (recombinant human collagen) produced using proprietary plant-based genetic engineering technology [2] Recent Developments - CollPlant will report its financial results for the second quarter on August 20, 2025, before the opening of U.S. financial markets [1] - In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, a leader in the dermal filler market [3]

Core Insights - Adia Nutrition Inc. has been approved as an in-network provider for Aetna health insurance, effective July 25, 2025, and is anticipating approval from United Healthcare by August 1, 2025, which will enhance access to its regenerative therapies and nutritional services [1][3][4] Group 1: Company Developments - The approval with Aetna allows Adia Med to serve approximately 39 million members across the U.S., leveraging Aetna's network of 1.8 million health professionals, including 828,000 primary care providers and specialists, and over 6,200 hospitals [3] - Adia Med is in the final stages of approval with United Healthcare, which holds a 15% market share and serves millions of members, further broadening access to its innovative treatments [3][5] - The company has begun submitting its first patient insurance claims through United Healthcare, indicating imminent integration into their network [4] Group 2: Financial Impact - Aetna processes claims for its 39 million members, with annual medical expenditures estimated in the tens of billions of dollars, covering a wide range of services [5] - United Healthcare similarly manages billions in annual medical payouts, supporting various services from primary care to specialized treatments, positioning Adia Nutrition to access significant reimbursement pathways [5] - These partnerships are expected to enhance affordability and reach for Adia Nutrition's regenerative medicine and nutritional services [5] Group 3: Market Context - The global stem cell market is valued at $15.1 billion, and the partnerships with Aetna and United Healthcare validate the clinical excellence of Adia Med's therapies, enabling transformative care delivery [6]

Core Viewpoint - Organogenesis Holdings Inc. will report its second quarter fiscal year 2025 financial results on August 7, 2025, after market close [1] Group 1: Financial Results Announcement - The financial results for the second quarter of fiscal year 2025 will be disclosed after the market closes on August 7, 2025 [1] - A conference call will be held at 5:00 p.m. Eastern Time on the same day to discuss the results and provide a corporate update [2] Group 2: Company Overview - Organogenesis Holdings Inc. specializes in regenerative medicine, focusing on advanced wound care and surgical and sports medicine markets [3] - The company offers a comprehensive portfolio of innovative regenerative products to meet patient needs across the continuum of care [3]

Core Insights - Adia Nutrition Inc. has partnered with CareCredit to offer financing options up to $25,000 for patient treatments, enhancing accessibility to advanced therapies in the $48.35 billion U.S. healthcare finance solutions market [1][3][4] Company Overview - Adia Nutrition Inc. is focused on regenerative medicine and personalized wellness solutions, with two main divisions: a supplement division providing premium organic supplements and a medical division specializing in advanced stem cell therapies [6] Financing Details - The partnership with CareCredit allows patients to finance treatments, including stem cell therapies, making them more attainable without financial strain [3][4] - CareCredit's financing limit of $25,000 provides greater flexibility compared to previous options, streamlining access to Adia's full range of services [4] Patient Accessibility - Patients can learn about eligibility and application for CareCredit financing through Adia Nutrition's website, which emphasizes a patient-centered approach with straightforward application processes and flexible repayment terms [5]

Core Viewpoint - Organogenesis Holdings Inc. supports the Centers for Medicare & Medicaid Services' (CMS) proposed new payment methodology for skin substitutes, emphasizing the need for payment rates to reflect clinical value and relative cost [1][2]. Company Overview - Organogenesis Holdings Inc. is a leading regenerative medicine company focused on developing, manufacturing, and commercializing solutions for advanced wound care and surgical and sports medicine markets [3][5]. - The company offers a comprehensive portfolio of innovative regenerative products to meet patient needs across the continuum of care [3][5]. Industry Context - The proposed payment structure by CMS aims to establish a per centimeter square payment methodology based on FDA classification for skin substitutes, which is expected to reduce Medicare spending and ensure consistent payment across care settings [2]. - The new payment approach is anticipated to enhance access to innovative wound healing technologies, which have been shown to reduce life-threatening amputations and complications [2]. Future Outlook - With over forty years of leadership in regenerative medicine, the company is well-positioned for growth in the evolving wound care market [2]. - The company remains committed to collaborating with CMS and other stakeholders to refine proposed policies that promote long-term stability and expand access to PMA products [2].

Core Insights - Adia Nutrition Inc. has opened its first licensed clinic, Adia Med of San Antonio, under a strategic license agreement, led by Dr. Michele DeLeon [1][2] - The clinic aims to expand access to innovative regenerative therapies in the U.S. and will offer FDA-registered products, including AdiaVita and AdiaLink [1][2] - A clinical study focusing on regenerative therapies for autism will be conducted in collaboration with Adia Med of Winter Park, highlighting the company's commitment to transformative healthcare solutions [2] Company Overview - Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) focused on revolutionizing healthcare and supplementation through two main divisions: a supplement division and a medical division specializing in stem cell therapies [3] - The medical division emphasizes treatments involving Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) [3] - The company is dedicated to empowering individuals by addressing nutritional needs and providing groundbreaking medical treatments [3]

NEW YORK, July 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of 3D Systems Corporation (NYSE: DDD). NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of DDD during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is August 12, 2025. There is no cost or obligation to you to participa ...

Core Insights - Creative Medical Technology Holdings, Inc. has received a Notice of Allowance for a U.S. patent related to treating heart failure and post-infarct pathological remodeling using its ImmCelz product, with the patent expected to be effective until at least 2040 [1][2]. Group 1: Patent and Product Details - The patent covers treatment for patients at risk of or already experiencing heart failure, utilizing the proprietary ImmCelz product [2]. - The total addressable market for heart failure treatment in the U.S. exceeds five million patients, with an additional six million patients suffering from chronic chest pain who may benefit from the ImmCelz product [2]. - ImmCelz is administered through an ultra-minimally invasive outpatient procedure [2]. Group 2: Company Strategy and Technology - The CEO of Creative Medical emphasized that the Notice of Allowance enhances the company's intellectual property portfolio and reflects the potential of its cell-based technology for developing therapies across various indications [3]. - The ImmCelz platform involves reprogramming a patient's immune cells outside the body with optimized cell-free factors before re-injecting them, which is believed to enhance their regenerative properties [4]. - Creative Medical is focused on pioneering regenerative medicine solutions across multiple indications, including pain management, neurology, and urology [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of 3D Systems Corporation regarding a class action lawsuit due to alleged misleading statements and omissions made by the company during a specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from August 13, 2024, to May 12, 2025 [3]. - Allegations include that 3D Systems understated the impact of weakened customer spending and overstated its resilience in challenging industry conditions [3]. - Additionally, the updated milestone criteria in the partnership with United Therapeutics Corporation are claimed to negatively impact the company's regenerative medicine program revenue [3]. Next Steps for Shareholders - Shareholders who purchased shares during the class period are encouraged to register for the class action by August 12, 2025 [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered losses due to deceit, fraud, and illegal business practices [5]. - The firm is committed to ensuring companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [5].

Group 1: Core Collaboration - Leigh Steinberg, a renowned sports agent, and Prof. Dr. Mike Chan, a leading stem cell scientist, have formed a groundbreaking alliance aimed at addressing brain trauma in athletes [2][4][29] - Their mission focuses on healing athletes affected by brain injuries through innovative regenerative medicine techniques [4][29] Group 2: Advocacy and Awareness - Steinberg has represented over 300 professional athletes and is a strong advocate for those suffering from long-term effects of concussions and chronic traumatic encephalopathy (CTE) [5][8] - The Leigh Steinberg Foundation has been established to raise awareness and funding for concussion and brain injury research, particularly in underserved communities [8][9] Group 3: Scientific Approach - Prof. Chan's work emphasizes the use of targeted precursor stem cells to treat brain injuries, which could potentially reverse aging effects and restore brain function [13][24] - The DDRR™ protocol developed by Prof. Chan includes Diagnose, Detox, Repair, and Rejuvenate phases, focusing on personalized treatment for brain injuries [13][14] Group 4: Research and Evidence - Research indicates that 1 in 3 former NFL players believe they have CTE, with significant rates of depression and cognitive difficulties among them [11] - Clinical trials have shown that stem cell infusions can significantly reduce inflammation and preserve brain tissue related to memory and cognition in trauma cases [25][26] Group 5: Future Vision - The partnership between Steinberg and Chan aims to set new global standards for post-career athlete care, focusing on long-term health and wellness [26][29] - The collaboration seeks to transform the narrative around brain injuries in sports, making them treatable conditions rather than career-ending sentences [29]